Skip to main content
. 2018 Apr 27;9(32):22509–22522. doi: 10.18632/oncotarget.25147

Figure 3. ER ligands modulate p53 function.

Figure 3

(A) Dot blot depicting the fold change of mRNA expression of p53 target genes in MCF-7 cells following treatment with vehicle (Control) or the ER subtype-specific ligands 17β-estradiol (E2, 10 nM), Diarylpropionitrile (DPN, 10 nM), or combination of E2 and 1 μM 4-hydroxytamoxifen (4-OHT) for 24 hours. Values were normalized to the untreated cells. (B) Dot blot representing the fold change of mRNA expression of p53 target genes in control and ERβ-expressing MCF-7 cells after treatment with 10 nM fulvestrant (ICI) for 24 hours. (C) mRNA levels of p53 target genes in MCF-7 cells following treatment with vehicle (Control), 20 μM cisplatin (Cis) or combination of 20 μM cisplatin and 10 nM DPN. Values were normalized to the untreated cells. In all graphs values represent the mean ± S.D. of three different experiments; *P ≤ 0.05.